Hangzhou Tigermed Consulting Co Stock | 300347.SZ | CNE100001KV8 | | October 2025

Date	Hangzhou Tigermed Consulting Co Price
9/30/2025	58.04 undefined
9/30/2025	58.00 undefined
9/29/2025	58.71 undefined
9/26/2025	59.29 undefined
9/25/2025	60.70 undefined
9/24/2025	60.99 undefined
9/24/2025	61.00 undefined
9/23/2025	57.74 undefined
9/23/2025	57.80 undefined
9/22/2025	59.12 undefined
9/22/2025	59.11 undefined
9/19/2025	58.71 undefined
9/19/2025	58.75 undefined
9/18/2025	59.66 undefined
9/18/2025	59.45 undefined
9/17/2025	60.22 undefined
9/17/2025	60.22 undefined
9/16/2025	60.86 undefined
9/16/2025	60.87 undefined
9/15/2025	61.73 undefined
9/15/2025	61.77 undefined
9/12/2025	60.98 undefined
9/12/2025	61.01 undefined
9/11/2025	61.22 undefined
9/10/2025	64.35 undefined
9/10/2025	64.22 undefined
9/9/2025	64.67 undefined
9/9/2025	64.66 undefined
9/8/2025	67.06 undefined
9/8/2025	67.19 undefined
9/5/2025	66.47 undefined
9/5/2025	66.58 undefined
9/4/2025	62.50 undefined
9/4/2025	62.42 undefined

Date	Hangzhou Tigermed Consulting Co Revenue	Hangzhou Tigermed Consulting Co EBIT	Hangzhou Tigermed Consulting Co Net Income
2030e	14.57 B undefined	0 undefined	0 undefined
2029e	12.87 B undefined	5.55 B undefined	0 undefined
2028e	11.23 B undefined	4.94 B undefined	0 undefined
2027e	9.06 B undefined	1.9 B undefined	1.75 B undefined
2026e	7.95 B undefined	1.53 B undefined	1.41 B undefined
2025e	7.11 B undefined	1.25 B undefined	1.19 B undefined
2024	6.6 B undefined	1.09 B undefined	405.14 M undefined
2023	7.38 B undefined	1.71 B undefined	2.02 B undefined
2022	7.09 B undefined	1.78 B undefined	2.01 B undefined
2021	5.21 B undefined	1.43 B undefined	2.87 B undefined
2020	3.19 B undefined	956.7 M undefined	1.75 B undefined
2019	2.8 B undefined	802.8 M undefined	841.6 M undefined
2018	2.3 B undefined	628 M undefined	472.2 M undefined
2017	1.69 B undefined	423.6 M undefined	301 M undefined
2016	1.17 B undefined	167.5 M undefined	140.7 M undefined
2015	957 M undefined	210.9 M undefined	156.3 M undefined
2014	624.6 M undefined	153.8 M undefined	125.5 M undefined
2013	336.5 M undefined	89 M undefined	94.1 M undefined
2012	254.3 M undefined	66.7 M undefined	67.7 M undefined
2011	193.3 M undefined	54 M undefined	47.8 M undefined
2010	122.8 M undefined	34.5 M undefined	31.7 M undefined
2009	62.8 M undefined	7.1 M undefined	7.8 M undefined

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022	2023	2024

0.02	0.04	0.09	0.56	0.53	0.45	0.24	0.54	0.61	0.7	2.11	9.99	8.57	8.41	7.81	7.48	2.14
0.02	0.02	0.05	0.09	0.13	0.3	0.38	0.45	0.63	0.78	1.16	1.32	2.1	2.09	3.03	3.63	3.86
1	2	5	8	10	10	42	72	67	58	64	119	75.85	82.78	98.29	109.23	131.19
0	0	0	0	0	0	0	0	0	1	1	5	6.1	6.1	22.2	23.4	31.96
1	21	8	4	8	21	23	36	34	64	41	220	94.79	260.73	153.97	103.3	134.07
0.04	0.09	0.14	0.66	0.68	0.79	0.69	1.09	1.35	1.6	3.37	11.65	10.85	10.85	11.11	11.34	6.3
0.02	0.02	0.02	0.05	0.08	0.15	0.19	0.2	0.2	0.26	0.43	0.68	1.12	1.14	1.34	1.49	1.7
0	0	0	0	0.02	0.05	0.19	0.46	0.88	1.33	2.36	5.37	9.5	9.5	11.8	13.22	16.77
0	0	0	0	0	0	0	0	0	0	0	0	75.85	0	0	0	0
0	0	8	9	10	19	14	13	17	28	96	142	250.64	250.64	338.12	371.13	336.88
0.01	0.01	0.01	0.01	0.02	0.34	0.47	0.6	1.05	1.03	1.16	1.45	1.78	1.78	2.49	2.76	3.23
0	1	3	2	2	15	50	17	87	36	122	223	219	219	380.99	492.47	341.58
0.03	0.03	0.04	0.07	0.13	0.57	0.92	1.29	2.24	2.68	4.16	7.86	12.95	12.89	16.34	18.34	22.37
0.07	0.12	0.19	0.73	0.81	1.36	1.61	2.39	3.58	4.28	7.53	19.51	23.8	23.74	27.45	29.68	28.67

30	40	40	53	107	215	433	475	500	500	750	872	872.44	872.44	872.42	872.42	864.95
0.01	0.03	0.03	0.49	0.44	0.38	0.18	0.67	1.27	1.32	1.71	12	11.89	11.89	11.85	11.71	10.77
0	0.03	0.08	0.14	0.19	0.28	0.39	0.48	0.72	1.1	1.94	3.48	6.09	6.09	7.66	9.21	9.13
0	0	0	0	0	-0.01	-0	0	-0	-0	0.03	-0.09	2.33	-0.16	0.06	0.09	0.09
0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.88	8.83	6.09
0.04	0.09	0.14	0.69	0.74	0.86	1	1.63	2.49	2.92	4.42	16.25	21.17	18.69	20.45	21.9	20.86
0	0	2	12	14	17	10	15	24	44	75	101	147.87	125.75	157.96	249.31	257.29
0	1	3	6	8	22	27	43	55	89	156	183	350.68	350.68	403.5	461.53	355.48
0.02	0.02	0.03	0.02	0.03	0.08	0.18	0.2	0.32	0.41	0.63	0.78	1.35	1.33	1.15	0.91	0.9
0	0	0	0	0	0.27	0.26	0.18	0.27	0.64	0.89	0.02	0.49	0.53	1.88	1.99	1.95
0	0	0	0	0	0	0	0	63	29	33	52	74.52	74.52	137.32	519.57	201.58
0.02	0.02	0.04	0.04	0.05	0.39	0.47	0.44	0.73	1.21	1.79	1.14	2.41	2.41	3.73	4.14	3.66
0	0	0	0	0	7	24	33	32	19	154	279	406.84	406.84	733.62	857.33	722.97
0	0	0	0	0	4	9	17	13	14	46	132	201.54	201.54	214.39	213.98	201.8
0	1	3	0	0	43	40	64	4	4	20	97	-3,351.33	114.88	87.9	17.13	19.92
0	0	0	0	0	0.05	0.07	0.11	0.05	0.04	0.22	0.51	-2.74	0.72	1.04	1.09	0.94
0.02	0.02	0.04	0.04	0.05	0.44	0.54	0.55	0.78	1.25	2.01	1.65	-0.33	3.14	4.77	5.23	4.61
0.07	0.12	0.18	0.73	0.8	1.3	1.55	2.18	3.27	4.16	6.43	17.9	20.84	21.83	25.22	27.12	25.47

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	2.87	0	0
0	0	0	0	0	0	0	0	0	0	0	0	188	0	329
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-7
3	-10	-16	-93	-104	-238	-462	-552	-671	-921	-1,157	-1,314	-98	-1,734	-2,420
0	0	0	0	0	0	0	0	0	0	0	0	-1,548	0	-285
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-3	-4	-15	-17	-26	-41	-59	-71	-127	-140	-234	-241	-321	-321	-594
0.02	0.03	0.04	0.02	0.08	0.04	0.19	0.19	0.32	0.52	0.53	1	1.42	1.42	1.36
-13	-8	-16	-21	-37	-38	-87	-61	-46	-91	-102	-156	-368	-368	-448
-34	-20	4	-22	-139	-219	-413	-530	-846	-366	-638	-2,367	-2,782	-2,782	-2,789
-20	-12	20	-1	-102	-181	-326	-468	-800	-274	-535	-2,210	-2,414	-2,414	-2,340
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0.23	-0.01	-0.05	0.08	0.34	0.18	-0.9	0.4	0.49	1.61
0	0	0	0	0	0	0	0	0	0	0	0	-227	0	-87
0	0.02	0	0.48	-0.04	0.12	0.01	0.49	0.7	0.01	1.43	9.34	-0.16	-0.16	0.81
0	0.02	0	0.48	0	-0.06	0.07	0.59	0.69	-0.2	1.52	10.51	-0.05	-0.37	-0.31
0	0	0	0	-43	-46	-46	-59	-62	-126	-266	-271	-284	-284	-491
0.01	0.07	0.11	0.6	0.1	0.27	0.51	0.98	1.28	1.76	3.26	10.48	1.95	1.9	3.78
8	18.3	22.5	-6.7	39.7	5.6	98.6	130.2	269	430.5	424.7	842.2	1,055.18	1,055.18	908.9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Hangzhou Tigermed Consulting Co Gross margin	Hangzhou Tigermed Consulting Co Profit margin	Hangzhou Tigermed Consulting Co EBIT margin	Hangzhou Tigermed Consulting Co Profit margin
2030e	33.99 %	0 %	0 %
2029e	33.99 %	43.09 %	0 %
2028e	33.99 %	43.96 %	0 %
2027e	33.99 %	20.91 %	19.36 %
2026e	33.99 %	19.28 %	17.71 %
2025e	33.99 %	17.6 %	16.75 %
2024	33.99 %	16.5 %	6.14 %
2023	38.53 %	23.2 %	27.42 %
2022	39.64 %	25.12 %	28.32 %
2021	43.55 %	27.42 %	55.13 %
2020	47.43 %	29.97 %	54.81 %
2019	46.48 %	28.64 %	30.02 %
2018	43.1 %	27.3 %	20.52 %
2017	42.94 %	25.11 %	17.84 %
2016	38.03 %	14.26 %	11.98 %
2015	44.12 %	22.04 %	16.33 %
2014	47.33 %	24.62 %	20.09 %
2013	45.05 %	26.45 %	27.96 %
2012	46.24 %	26.23 %	26.62 %
2011	45.11 %	27.94 %	24.73 %
2010	45.6 %	28.09 %	25.81 %
2009	34.39 %	11.31 %	12.42 %

Date	Hangzhou Tigermed Consulting Co Sales per Share	Hangzhou Tigermed Consulting Co EBIT per share	Hangzhou Tigermed Consulting Co Earnings per Share
2030e	16.88 undefined	0 undefined	0 undefined
2029e	14.91 undefined	0 undefined	0 undefined
2028e	13.02 undefined	0 undefined	0 undefined
2027e	10.5 undefined	0 undefined	2.03 undefined
2026e	9.21 undefined	0 undefined	1.63 undefined
2025e	8.23 undefined	0 undefined	1.38 undefined
2024	7.65 undefined	1.26 undefined	0.47 undefined
2023	8.53 undefined	1.98 undefined	2.34 undefined
2022	8.19 undefined	2.06 undefined	2.32 undefined
2021	5.99 undefined	1.64 undefined	3.3 undefined
2020	4 undefined	1.2 undefined	2.19 undefined
2019	3.76 undefined	1.08 undefined	1.13 undefined
2018	3.07 undefined	0.84 undefined	0.63 undefined
2017	2.25 undefined	0.56 undefined	0.4 undefined
2016	1.67 undefined	0.24 undefined	0.2 undefined
2015	1.47 undefined	0.32 undefined	0.24 undefined
2014	0.98 undefined	0.24 undefined	0.2 undefined
2013	0.53 undefined	0.14 undefined	0.15 undefined
2012	0.48 undefined	0.13 undefined	0.13 undefined
2011	0.4 undefined	0.11 undefined	0.1 undefined
2010	0.26 undefined	0.07 undefined	0.07 undefined
2009	0.15 undefined	0.02 undefined	0.02 undefined

Date	Hangzhou Tigermed Consulting Co Dividend
2027e	0.32 undefined
2026e	0.25 undefined
2019e	0.23 undefined
2018e	0.13 undefined
2017e	0.07 undefined
2016e	0.07 undefined
2015e	0.07 undefined
2014e	0.07 undefined
2013e	0.07 undefined
2025	0.3 undefined
2024	0.57 undefined
2023	0.55 undefined
2022	0.5 undefined
2021	0.3 undefined
2020	0.28 undefined
2019e	0.23 undefined
2018e	0.13 undefined
2017e	0.07 undefined
2016e	0.07 undefined
2015e	0.07 undefined
2014e	0.07 undefined
2013e	0.07 undefined

Date	Hangzhou Tigermed Consulting Co Payout ratio
2030e	15.93 %
2029e	15.82 %
2028e	16.12 %
2027e	15.84 %
2026e	15.49 %
2025e	17.01 %
2024	15.03 %
2023	14.45 %
2022	21.55 %
2021	9.09 %
2020	12.69 %
2019	20.65 %
2018	21.16 %
2017	16.67 %
2016	33.35 %
2015	27.79 %
2014	33.35 %
2013	44.47 %
2012	14.45 %
2011	14.45 %
2010	14.45 %
2009	14.45 %

Date	EPS Estimate	EPS Actual	Quarterly report
6/30/2025	0.35	0.26 (-26.39 %)	2025 Q2
3/31/2025	0.27	0.19 (-29.03 %)	2025 Q1
12/31/2024	0.53	-0.47 (-189.32 %)	2024 Q4
9/30/2024	0.54	0.37 (-31.53 %)	2024 Q3
6/30/2024	0.5	0.3 (-40.12 %)	2024 Q2
3/31/2024	0.54	0.27 (-49.66 %)	2024 Q1
12/31/2023	0.46	0.17 (-63.33 %)	2023 Q4
9/30/2023	0.75	0.57 (-24.4 %)	2023 Q3
6/30/2023	0.66	0.95 (44.11 %)	2023 Q2
3/31/2023	0.62	0.66 (6.43 %)	2023 Q1
12/31/2022	0.63	0.46 (-26.46 %)	2022 Q4
9/30/2022	0.67	0.48 (-28.39 %)	2022 Q3
6/30/2022	0.65	0.78 (20.23 %)	2022 Q2
3/31/2022	0.63	0.6 (-5.05 %)	2022 Q1
12/31/2021	0.45	1.27 (181.28 %)	2021 Q4
9/30/2021	0.41	0.61 (48.94 %)	2021 Q3
6/30/2021	0.55	0.92 (68.68 %)	2021 Q2
3/31/2021	0.39	0.52 (32.01 %)	2021 Q1
12/31/2020	0.18	0.49 (166.89 %)	2020 Q4
9/30/2020	0.35	0.39 (11.62 %)	2020 Q3
6/30/2020	0.28	0.99 (257.45 %)	2020 Q2
3/31/2020	0.28	0.34 (21.02 %)	2020 Q1
12/31/2019	0.33	0.43 (27.78 %)	2019 Q4
9/30/2019	0.22	0.23 (6.48 %)	2019 Q3
6/30/2019	0.26	0.28 (5.5 %)	2019 Q2
3/31/2019	0.19	0.19 (-0.31 %)	2019 Q1
12/31/2018	0.18	0.21 (14.65 %)	2018 Q4
9/30/2018	0.16	0.13 (-19.47 %)	2018 Q3
6/30/2018	0.16	0.16 (3.81 %)	2018 Q2
3/31/2018	0.12	0.13 (5.47 %)	2018 Q1
12/31/2017	0.14	0.13 (-5.23 %)	2017 Q4

%	Name	Stocks	Change	Date
20.53664 %	Ye (Xiaoping)	177,239,541	0	3/31/2025
5.98602 %	Cao (Xiaochun)	51,661,774	0	3/31/2025
3.58652 %	Zhong Ou Asset Management Co., Ltd.	30,953,082	926,000	3/31/2025
2.68689 %	E Fund Management Co. Ltd.	23,188,984	-1,049,558	3/31/2025
1.97172 %	Hwabao WP Fund Management Co., Ltd.	17,016,750	146,500	3/31/2025
1.91716 %	GF Fund Management Co., Ltd.	16,545,888	314,359	12/31/2024
1.16012 %	Shi (Xiao Li)	10,012,321	-10,700	3/31/2025
1.11808 %	AEGON-INDUSTRIAL Fund Management Co., Ltd.	9,649,465	-322,188	3/31/2025
0.95751 %	Harvest Fund Management Co., Ltd.	8,263,724	215,200	6/30/2025
0.94654 %	Yinhua Fund Management Co., Ltd.	8,169,050	3,350,750	12/31/2024
0.93796 %	Tianhong Asset Management Co., Ltd.	8,094,961	1,014,694	12/31/2024
0.88859 %	HuaAn Fund Management Co., Ltd.	7,668,850	2,151,001	12/31/2024
0.80767 %	China Asset Management Co., Ltd.	6,970,563	-1,224,730	12/31/2024
0.71750 %	China Universal Asset Management Co., Ltd.	6,192,319	1,657,577	12/31/2024
0.55255 %	China Southern Asset Management Co. Ltd.	4,768,690	773,588	12/31/2024
0.46185 %	Hermes Capital FIZ	3,985,976	-101,248	2/28/2025
0.37172 %	ICBC UBS Asset Management Co., Ltd.	3,208,100	1,921,001	12/31/2024
0.31401 %	Galaxy Asset Management Co., Ltd.	2,710,038	1,001,500	12/31/2024
0.24645 %	Bank of Communications Schroder Fund Management Co., Ltd.	2,126,937	-15,310,803	12/31/2024
0.24183 %	Guotai Asset Management Co., Ltd.	2,087,067	14,318	12/31/2024
0.20271 %	SWS MU Fund Management Co., Ltd.	1,749,491	1,674,200	12/31/2024
0.20093 %	Fullgoal Fund Management Co., Ltd.	1,734,076	-1,878,174	12/31/2024
0.20052 %	The Vanguard Group, Inc.	1,730,536	0	7/31/2025
0.17112 %	Morgan Stanley Investment Management (China) Company Limited.	1,476,800	778,300	12/31/2024
0.15892 %	GLG Partners LP	1,371,570	1,371,570	6/30/2025
0.15682 %	abrdn Asia Limited	1,353,394	0	6/30/2025
0.15354 %	Norges Bank Investment Management (NBIM)	1,325,114	172,012	12/31/2024
0.13637 %	UBS Asset Management (Hong Kong) Limited	1,176,954	-169,200	4/30/2025
0.13494 %	INVESCO Great Wall Fund Management Co. Ltd.	1,164,583	261,439	12/31/2024
0.13475 %	Penghua Fund Management Co., Ltd.	1,162,946	581,900	12/31/2024
0.09699 %	Zhong Hai Fund Management Co., Ltd.	837,100	-872,719	12/31/2024
0.08850 %	Huashang Fund Management Co., Ltd.	763,800	100,600	12/31/2024
0.07925 %	Rongtong Fund Management Co., Ltd.	683,966	-301,200	12/31/2024
0.07676 %	BlackRock Institutional Trust Company, N.A.	662,512	3,000	7/31/2025
0.05997 %	CCB Principal Asset Management Co., Ltd.	517,575	125,467	12/31/2024
0.05533 %	Bosera Asset Management Co., Ltd.	477,510	-41,400	12/31/2024
0.05374 %	GLG LLC	463,767	463,767	6/30/2025
0.05275 %	Golden Eagle Asset Management Co., Ltd.	455,244	261,100	12/31/2024
0.05031 %	Amundi Asset Management, SAS	434,172	2,400	7/31/2025
0.04867 %	BlackRock Advisors (UK) Limited	420,021	-6,400	7/31/2025
0.04802 %	Harvest Global Investments Limited	414,429	0	7/31/2025
0.04531 %	ABC-CA Fund Management Co., Ltd.	391,020	335,520	12/31/2024
0.04428 %	Great Wall Fund Management Co., Ltd.	382,159	-158,276	12/31/2024
0.04371 %	China Asset Management (Hong Kong) Limited	377,256	-38,700	6/30/2025
0.03834 %	Changsheng Fund Management Co., Ltd.	330,870	9,645	12/31/2024
0.03809 %	PengYang Asset Management Co., Ltd	328,693	-22,600	12/31/2024
0.03564 %	State Street Global Advisors (US)	307,576	4,300	7/31/2025
0.03448 %	Wellington Management Company, LLP	297,579	-29,160	6/30/2025
0.03427 %	Topsperity Fund Management Co., Ltd.	295,800	-47,500	12/31/2024
0.03069 %	Bank of China Investment Management Co., Ltd.	264,900	195,200	12/31/2024
0.02874 %	Lion Fund Management Co., Ltd.	248,053	-199,300	12/31/2024
0.02761 %	AXA-SPDB Investment Managers Co., Ltd.	238,326	228,300	12/31/2024
0.02706 %	Fidelity Management & Research (Hong Kong) Limited	233,505	0	6/30/2025
0.02634 %	China Post & Capital Fund Management Co., Ltd.	227,300	156,300	12/31/2024
0.02465 %	CPIC Fund Management Co., Ltd.	212,698	11,400	12/31/2024
0.02452 %	Maxwealth Fund Management Co., Ltd.	211,633	59,401	12/31/2024
0.02298 %	BlackRock (Singapore) Limited	198,335	37,632	7/31/2025
0.02228 %	Western Leadbank Fund Management Co., Ltd.	192,259	53,600	12/31/2024
0.02113 %	Hermes Investment Management Ltd.	182,335	-98,288	3/31/2025
0.01996 %	Truvalue Asset Management Co., Ltd.	172,300	166,200	12/31/2024
0.01976 %	Tibet Eastmoney Fund Management Co., Ltd.	170,500	19,700	12/31/2024
0.01969 %	JT Asset Management Co., Ltd.	169,958	59,258	12/31/2024
0.01868 %	Minsheng Royal Fund Management Company Ltd.	161,200	-109,500	12/31/2024
0.01847 %	SEB Asset Management (Denmark)	159,373	10	6/30/2025
0.01828 %	Wanjia Asset Management Co., Ltd.	157,800	-161,500	12/31/2024
0.01815 %	BOC International (China) Ltd.	156,600	-5,100	12/31/2024
0.01762 %	Taikang Asset Management Co., Ltd.	152,107	4,100	12/31/2024
0.01688 %	UBS SDIC Fund Management Co., Ltd.	145,712	86,200	12/31/2024
0.01688 %	Huatai Securities (Shanghai) Asset Management Co., Ltd.	145,700	31,000	12/31/2024
0.01622 %	Nikko Asset Management Asia Limited	140,004	140,004	11/30/2024
0.01612 %	Ninety One North America, Inc.	139,156	0	4/30/2025
0.01530 %	Ninety One SA Pty Ltd.	132,056	132,056	10/31/2024
0.01448 %	Mellon Investments Corporation	124,967	0	7/31/2025
0.01443 %	Mirae Asset Global Investments Co., Ltd.	124,562	229	6/30/2025
0.01397 %	Everbright PGIM Fund Management Co., Ltd.	120,525	-104,400	12/31/2024
0.01356 %	New China Fund Management Co., Ltd.	117,000	104,800	12/31/2024
0.01253 %	Baillie Gifford Overseas Ltd.	108,100	-20,500	6/30/2025
0.01219 %	Industrial Securities Assets Management Ltd.	105,200	70,900	12/31/2024
0.01193 %	Ping An Fund Management Company Limited	103,000	-137,400	12/31/2024
0.01179 %	Geode Capital Management, L.L.C.	101,757	0	6/30/2025
0.01142 %	Baoying Fund Management Co., Ltd.	98,600	98,600	12/31/2024
0.01059 %	BOSC Asset Management Co., Ltd.	91,400	70,700	12/31/2024
0.00990 %	CITIC Prudential Fund Management Co., Ltd.	85,400	800	12/31/2024
0.00990 %	Xingyin Fund Management Co., Ltd.	85,400	12,100	12/31/2024
0.00985 %	Beixin Ruifeng Fund Management Co., Ltd.	85,000	10,000	12/31/2024
0.00975 %	Amundi Japan Ltd.	84,153	6,900	7/31/2025
0.00973 %	Green Fund Management Co., Ltd.	84,000	84,000	12/31/2024
0.00928 %	China Life AMP Asset Management Co., Ltd	80,109	37,200	12/31/2024
0.00826 %	BlackRock Investment Management (UK) Ltd.	71,300	37,000	4/30/2025
0.00754 %	Northern Trust Global Investments Limited	65,059	255	6/30/2025
0.00750 %	Charles Schwab Investment Management, Inc.	64,700	0	7/31/2025
0.00738 %	Founder Fubon Fund Management Co., Ltd.	63,700	3,500	12/31/2024
0.00728 %	Krane Funds Advisors, LLC	62,850	3,800	7/31/2025
0.00677 %	JPMorgan Asset Management (China) Company Limited.	58,427	-442,979	12/31/2024
0.00672 %	PGGM Vermogensbeheer B.V.	57,969	180	3/31/2025
0.00647 %	Samsung Asset Management Co., Ltd.	55,863	-105	6/30/2025
0.00630 %	State Street Global Advisors (UK) Ltd.	54,409	0	7/31/2025
0.00616 %	California State Teachers Retirement System	53,200	-220,531	6/30/2024
0.00596 %	CSOP Asset Management Limited	51,400	-4,700	6/30/2025
0.00541 %	Golden Trust Sinopac Fund Management Co., Ltd.	46,700	-672,300	12/31/2024

What values and corporate philosophy does Hangzhou Tigermed Consulting Co represent?

Hangzhou Tigermed Consulting Co Ltd represents values of trust, innovation, and excellence in the field of clinical research and drug development. As a leading contract research organization, Tigermed is committed to providing high-quality services and solutions to pharmaceutical companies globally. With a strong focus on integrity and professionalism, the company aims to assist clients in achieving their clinical development goals efficiently. Moreover, Tigermed values collaboration, aiming to foster meaningful partnerships with its clients and professionals in the healthcare industry. Through cutting-edge technology and a customer-centric approach, Hangzhou Tigermed Consulting Co Ltd strives to be a reliable and strategic partner in advancing healthcare outcomes.

In which countries and regions is Hangzhou Tigermed Consulting Co primarily present?

Hangzhou Tigermed Consulting Co Ltd is primarily present in China, as it is a Chinese company. However, it also has a significant presence in other countries and regions. With its global expansion strategy, Hangzhou Tigermed Consulting Co Ltd has established branches and offices in numerous locations worldwide. These include the United States, Japan, South Korea, Europe, Australia, and Southeast Asia. This widespread presence allows Hangzhou Tigermed Consulting Co Ltd to offer its comprehensive range of pharmaceutical and clinical research services to clients internationally.

What significant milestones has the company Hangzhou Tigermed Consulting Co achieved?

Hangzhou Tigermed Consulting Co Ltd has achieved significant milestones in its history. As a leading contract research organization (CRO), the company has successfully established a global presence and expanded its service offerings. It has demonstrated its expertise in clinical research, regulatory affairs, and data management, serving clients across various therapeutic areas. Tigermed Consulting has also formed strategic partnerships with renowned pharmaceutical companies, positioning itself as a trusted partner in drug development and clinical trials. With its commitment to innovation and quality, Hangzhou Tigermed Consulting Co Ltd continues to make substantial advancements in the field of healthcare and contribute to improved patient outcomes.

What is the history and background of the company Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co Ltd is a leading contract research organization (CRO) based in China. Founded in 2004, the company has rapidly grown to become one of the largest independent CROs in the country. Tigermed specializes in providing comprehensive clinical research and development services to pharmaceutical and biotech companies globally. With a strong focus on clinical trial management, regulatory affairs, and data management, Tigermed has established a solid reputation for delivering high-quality solutions to its clients. The company's commitment to excellence and extensive experience in the industry has enabled it to forge strong partnerships and contribute significantly to the advancement of healthcare research.

Who are the main competitors of Hangzhou Tigermed Consulting Co in the market?

Some of the main competitors of Hangzhou Tigermed Consulting Co Ltd in the market include PPD Inc., ICON plc, QuintilesIMS, PAREXEL International Corporation, and Wuxi AppTec.

In which industries is Hangzhou Tigermed Consulting Co primarily active?

Hangzhou Tigermed Consulting Co Ltd is primarily active in the pharmaceutical and biotech industries.

What is the business model of Hangzhou Tigermed Consulting Co?

The business model of Hangzhou Tigermed Consulting Co Ltd revolves around providing comprehensive and integrated clinical research services to support the development and marketing of pharmaceutical, biotechnological, and medical device products. As a leading Contract Research Organization (CRO) in China, Tigermed offers a wide range of services including project planning, clinical trial management, regulatory affairs, data management, statistical analysis, and quality assurance. By leveraging their expertise, experience, and strategic partnerships, Hangzhou Tigermed Consulting Co Ltd caters to the growing needs of domestic and international clients in the healthcare industry.

What is the P/E ratio of Hangzhou Tigermed Consulting Co 2025?

The Hangzhou Tigermed Consulting Co P/E ratio is 42.08.

What is the P/S ratio of Hangzhou Tigermed Consulting Co 2025?

The Hangzhou Tigermed Consulting Co P/S ratio is 7.05.

What is the Quality Investing of Hangzhou Tigermed Consulting Co?

The Quality Investing for Hangzhou Tigermed Consulting Co is 6/10.

What is the revenue of Hangzhou Tigermed Consulting Co 2025?

The expected Hangzhou Tigermed Consulting Co revenue is 7.11 B CNY.

How high is the profit of Hangzhou Tigermed Consulting Co 2025?

The expected Hangzhou Tigermed Consulting Co profit is 1.19 B CNY.

What is the business model of Hangzhou Tigermed Consulting Co

The Hangzhou Tigermed Consulting Co Ltd is a leading company in the field of clinical research, offering a wide range of services to its customers. The company was founded in 2004 and has its headquarters in Hangzhou, China. With offices in various cities in China, Europe, and the USA, the company now has over 800 employees worldwide. The business model of Tigermed Consulting is to support companies in developing and bringing new products to market. To this end, the company offers a wide range of services that span the entire product lifecycle. The company provides customers with support in the planning, execution, and evaluation of clinical studies, following applicable regulations and guidelines. The company specializes in clinical studies, regulatory affairs, medical devices, biostatistics, and medical writing services. Tigermed Consulting offers unique services to its customers, providing comprehensive solutions for their clinical studies, regulatory matters, and medical products. The company has experienced significant growth in recent years by offering a broad range of customizable services tailored to the specific needs of its customers. Overall, the business model of Tigermed Consulting aims to help its customers stay competitive and successfully bring their products to market. In a world driven by new technologies and innovations, it is important to leverage the expertise of companies like Tigermed Consulting to operate a successful and profitable business.

What is the Hangzhou Tigermed Consulting Co dividend?

Hangzhou Tigermed Consulting Co pays a dividend of 0.5 CNY distributed over payouts per year.

How often does Hangzhou Tigermed Consulting Co pay dividends?

The dividend cannot currently be calculated for Hangzhou Tigermed Consulting Co or the company does not pay out a dividend.

What is the Hangzhou Tigermed Consulting Co ISIN?

The ISIN of Hangzhou Tigermed Consulting Co is CNE100001KV8.

What is the Hangzhou Tigermed Consulting Co ticker?

The ticker of Hangzhou Tigermed Consulting Co is 300347.SZ.

How much dividend does Hangzhou Tigermed Consulting Co pay?

Over the past 12 months, Hangzhou Tigermed Consulting Co paid a dividend of 0.57 CNY . This corresponds to a dividend yield of about 0.98 %. For the coming 12 months, Hangzhou Tigermed Consulting Co is expected to pay a dividend of 0.25 CNY.

What is the dividend yield of Hangzhou Tigermed Consulting Co?

The current dividend yield of Hangzhou Tigermed Consulting Co is 0.98 %.

When does Hangzhou Tigermed Consulting Co pay dividends?

Hangzhou Tigermed Consulting Co pays a quarterly dividend. This is distributed in the months of June, August, August, July.

How secure is the dividend of Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co paid dividends every year for the past 0 years.

What is the dividend of Hangzhou Tigermed Consulting Co?

For the upcoming 12 months, dividends amounting to 0.25 CNY are expected. This corresponds to a dividend yield of 0.44 %.

In which sector is Hangzhou Tigermed Consulting Co located?

Hangzhou Tigermed Consulting Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hangzhou Tigermed Consulting Co from 6/17/2025 amounting to 0.3 CNY, you needed to have the stock in your portfolio before the ex-date on 6/17/2025.

When did Hangzhou Tigermed Consulting Co pay the last dividend?

The last dividend was paid out on 6/17/2025.

What was the dividend of Hangzhou Tigermed Consulting Co in the year 2024?

In the year 2024, Hangzhou Tigermed Consulting Co distributed 0.55 CNY as dividends.

In which currency does Hangzhou Tigermed Consulting Co pay out the dividend?

The dividends of Hangzhou Tigermed Consulting Co are distributed in CNY.

Scope 1 - Direct Emissions	116.82
Scope 2 - Indirect emissions from purchased energy	12,944.04
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions	13,060.86
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Percentage of female employees	83.557
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

Hangzhou Tigermed Consulting Co Ticker	Hangzhou Tigermed Consulting Co FIGI
300347:CH	BBG002PKXG01
300347:CS	BBG002QKZ361
300347:C2	BBG00F13DR59

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
0.06	0.12	0.19	0.25	0.34	0.62	0.96	1.17	1.69	2.3	2.8	3.19	5.21	7.09	7.38	6.6	7.11	7.95	9.06	11.23	12.87	14.57
-	96.77	58.20	31.61	32.28	85.71	53.37	22.68	43.70	36.34	21.87	13.88	63.31	35.91	4.22	-10.58	7.62	11.81	14.05	23.98	14.56	13.19
33.87	45.90	45.08	46.06	44.94	47.28	44.10	37.99	42.92	43.09	46.45	47.43	43.54	39.63	38.53	33.98	31.58	28.24	24.77	19.98	17.44	15.40
0.02	0.06	0.09	0.12	0.15	0.3	0.42	0.45	0.72	0.99	1.3	1.51	2.27	2.81	2.85	2.24	0	0	0	0	0	0
0.01	0.03	0.05	0.07	0.09	0.13	0.16	0.14	0.3	0.47	0.84	1.75	2.87	2.01	2.02	0.41	1.19	1.41	1.75	0	0	0
-	342.86	51.61	42.55	40.30	32.98	24.80	-10.26	115.00	56.81	78.18	107.97	64.32	-30.20	0.90	-79.99	193.83	18.24	24.66	-	-	-
-	-	-	-	0.13	0.13	0.13	0.13	0.13	0.27	0.47	0.28	0.30	0.50	0.55	0.57	0.30	0.25	0.32	-	-	-
0	0	0	0	0	0	0	0	0	107.69	74.07	-40.43	7.14	66.67	10	3.64	-47.37	-16.67	28	0	0	0
405.2	473	480	533.6	640.8	638.1	650	703.3	750.3	750.3	744.8	799	870.96	864.89	865.32	863.04	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Discover undervalued stocks with Eulerpool.

Hangzhou Tigermed Consulting Co Stock 300347.SZ

Price

Price

Ticker300347.SZ

ISINCNE100001KV8

Hangzhou Tigermed Consulting Co stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Hangzhou Tigermed Consulting Co Stock Price History

Hangzhou Tigermed Consulting Co Revenue, EBIT, Net Income

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Hangzhou Tigermed Consulting Co Revenue, EBIT and net profit per share

Hangzhou Tigermed Consulting Co Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Hangzhou Tigermed Consulting Co stock margins

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Hangzhou Tigermed Consulting Co Margin History

Hangzhou Tigermed Consulting Co Stock Sales Revenue, EBIT, Earnings per Share

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Hangzhou Tigermed Consulting Co Revenue, EBIT and net profit per share

Hangzhou Tigermed Consulting Co business model

Hangzhou Tigermed Consulting Co SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

The World’s Best Investors Are On Eulerpool

Hangzhou Tigermed Consulting Co Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Hangzhou Tigermed Consulting Co historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Hangzhou Tigermed Consulting Co shares outstanding

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Hangzhou Tigermed Consulting Co stock splits

Hangzhou Tigermed Consulting Co dividend history and estimates

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Ticker
300347.SZ

ISIN
CNE100001KV8